Abstract 1011P
Background
TACE is the recommended first-line treatment for intermediate-stage HCC. The side effects and complications associated with TACE treatment have been described previously. The aim of this study is to explore the patient and caregiver experience associated with TACE.
Methods
A cross-sectional study was conducted Jan–May 2019 in France, Germany, Italy, Spain, UK, Japan, Taiwan and China. Physicians completed case report forms (CRFs) for patients who had received TACE within 30 days of data capture. The patient survey included the Functional Assessment of Cancer Therapy – Hepatobiliary (FACT-Hep), a 45-item instrument evaluating patients’ health-related quality of life (HRQoL) (score range 0-180; higher scores indicate better QoL). The caregiver survey included the Zarit Burden Interview (ZBI), a 22-item instrument assessing caregiving burden (score range 0-88; higher scores indicate higher burden).
Results
131 matched CRFs, patient surveys and caregiver surveys were available from 4 countries: France, Germany, Spain and China. Mean patient age was 61 years (SD ±8.76), 87% male, and 47% were Child Pugh A class versus 53% class B. Symptoms collected by the physicians included fatigue (69%), nausea (54%) and abdomen pain (50%). Patients reported a mean FACT-Hep score of 107.1 (SD ±23.66). Caregivers had a mean age of 52 years (SD ±13.07), 82% female and 76% were partners/spouses. Caregivers provided a mean of 36.5 hours care per week (SD ±39.8) and over a third (35%) felt stress or anxiety was brought on or worsened due to caregiving. Caregivers reported a mean ZBI score of 30.4 (SD 14.54) and 26% reported a ‘moderate to severe’ or ‘severe’ score. As patients’ HRQoL (FACT-Hep) worsened, caregiver burden (ZBI) was greater (R2 = 0.281).
Conclusions
This study highlights the impact of caregiving associated with TACE among patients with HCC. Caregivers are required to provide support in a number of ways, resulting in reported increases in anxiety and stress, with a clear link between patient HRQoL and caregiving burden. Improving the treatment options available for intermediate-stage HCC may help address the impact of caregiving.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bristol Myers Squibb.
Funding
Bristol Myers Squibb.
Disclosure
J. Edeline: Honoraria (self): Boston Scientific; Honoraria (self), Advisory/Consultancy: Eisai; Advisory/Consultancy: Bristol Myers Squibb; Advisory/Consultancy: MSD; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Bayer; Advisory/Consultancy: Ipsen; Advisory/Consultancy: Roche; Research grant/Funding (institution): Beigene; Travel/Accommodation/Expenses: Amgen. T. Bailey: Full/Part-time employment, Adelphi Real World received consultancy fees from Bristol Myers Squibb: Adelphi Real World. G. Thompson: Full/Part-time employment: Bristol Myers Squibb. T. Wisniewski: Full/Part-time employment: Bristol Myers Squibb. G. Taylor-Stokes: Full/Part-time employment, Adelphi Real World received consultancy fees from Bristol Myers Squibb: Adelphi Real World. D. Begic: Full/Part-time employment: Bristol Myers Squibb. Y. Bennai: Full/Part-time employment: Bristol Myers Squibb.